HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa

Documenti analoghi

• Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
  di: Paton, Nicholas I, et al.
  Pubblicazione: (2017)
• Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure
  di: Kyeyune, Fred, et al.
  Pubblicazione: (2016)
• Evolution of drug resistance after virologic failure of a first highly active antiretroviral therapy regimen in Uganda
  di: Reynolds, Steven J., et al.
  Pubblicazione: (2009)
• Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period
  di: Kyeyune, Fred, et al.
  Pubblicazione: (2013)
• Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
  di: Hakim, James G, et al.
  Pubblicazione: (2018)